Life Sciences

  • December 10, 2025

    Akerman Hires DOJ Civil Division Lawyer For Healthcare Team

    Akerman LLP has brought on a former member of the U.S. Department of Justice's Civil Division, who will be joining the healthcare practice group as a partner in the firm's Washington, D.C., office, according to an announcement on Tuesday.

  • December 10, 2025

    VC Apple Tree Hits Ch. 11 After Row With Russian Billionaire

    Biotechnology investor Apple Tree Life Sciences Inc. and affiliates filed for Chapter 11 protection in Delaware bankruptcy court, days after a Chancery Court judge ordered a Russian billionaire who partnered with the fund to cough up $97 million that Apple Tree demanded to support its struggling medical companies.

  • December 10, 2025

    Weil, Reed Smith Build WTW's Newfront Buy For Up To $1.3B

    Advisory, brokerage and solutions company WTW, advised by Weil Gotshal & Manges LLP, announced Wednesday it had agreed to acquire Reed Smith LLP-led broker Newfront for up to $1.3 billion in a deal that will expand WTW's reach in the middle market and presence in technology, fintech and life sciences.

  • December 09, 2025

    Generic-Drug Group Backs House Bill On Skinny Labels

    An industry group representing the generic and biosimilar drug manufacturing sector has applauded the introduction of a U.S. House of Representatives bill titled The Skinny Labels, Big Savings Act, saying it will reduce prices across healthcare.

  • December 09, 2025

    Conn. Seems Open To Limits On Drug Price Cap Enforcement

    The state of Connecticut suggested Tuesday that drug sales to the state were not the same as drug sales "in this state" as defined by state law, a stance drug manufacturers promised to leverage in their efforts to block an impending drug price cap.

  • December 09, 2025

    NJ Drugmaker, Chubb Settle $6.5M Defense Costs Suit

    A New Jersey pharmaceutical company and Chubb have reached a settlement to end a lawsuit alleging the insurer owes nearly $6.5 million in outstanding legal fees stemming from a multibillion-dollar arbitration dispute over the development of a COVID-19 drug, according to a stipulation of dismissal from the companies. 

  • December 09, 2025

    Expert Invoices Discoverable In J&J Talc MDL, Judge Says

    A New Jersey federal judge said Monday that the plaintiffs steering committee can receive invoices for Johnson & Johnson's experts' work relating to multidistrict litigation alleging the use of talcum powder caused ovarian cancer and mesothelioma, but only after it produces its own expert invoices.

  • December 09, 2025

    Mistrial Declared In Fla. Opioid Case Against Pharmacies

    A Florida state judge declared a mistrial following a hung jury after two weeks of deliberations in a lawsuit brought by hospitals alleging that Walmart, Walgreens and CVS pharmacies negligently doled out painkillers and contributed to the opioid crisis. 

  • December 09, 2025

    Hagens Berman's Novel DOJ Referral May Have Chilling Effect

    A Pennsylvania federal judge's unusual decision to refer prominent plaintiffs firm Hagens Berman LLP to the U.S. Department of Justice for possible criminal investigation over its pursuit of claims related to morning sickness drug thalidomide could have a chilling effect on lawyers' advocacy, law professors and attorneys said.

  • December 09, 2025

    Medical Appliance Co. Seeks Coverage For SEC Investigation

    A Connecticut-based medical device technology company told a federal court that its insurer wrongfully denied coverage for an investigation by the Securities and Exchange Commission, alleging in a new lawsuit that the federal government's inquiry into the company's insured members triggered its directors and officers policy. 

  • December 09, 2025

    Cooley Adds 30-Person Life Sciences IP Team From Dechert

    A trio of Dechert LLP partners, including the co-chair of its global intellectual property practice, have joined Cooley LLP alongside a team of special counsel, associates and patent agents, the firm announced Tuesday.

  • December 09, 2025

    Teleflex To Divest Multiple Units In Deals Topping $2B

    Simpson Thacher & Bartlett LLP-advised Teleflex Inc. said Tuesday it has agreed to sell several units to private equity firms Montagu and Kohlberg, and to Britain's Intersurgical Ltd., for a combined $2.03 billion in cash.

  • December 08, 2025

    Inari Loses Fed. Circ. Bid To Save Corn Seed Patent Review

    The Federal Circuit Monday rejected Inari Agriculture's mandamus petition claiming the Patent Trial and Appeal Board used an unfairly high standard when denying its request for post-grant review of a Corteva Inc. unit's patent. 

  • December 08, 2025

    1st Circ. Keeps Planned Parenthood Funding Ban In Place

    The First Circuit on Monday issued an administrative stay that temporarily keeps in place a ban on Medicaid funding for Planned Parenthood, pausing a lower court's ruling.

  • December 08, 2025

    What To Do When Jurors Don't 'Trust The Science'

    The pandemic and initiatives from the second administration of President Donald Trump challenging decades of established scientific norms have made science more politicized, and attorneys say picking a jury and presenting scientific evidence is increasingly challenging.

  • December 08, 2025

    4th Circ. Backs EIDP In Dispute Over Annuity Reductions

    The Fourth Circuit backed agricultural chemical giant EIDP Inc. and its retirement plan administrator in a Monday opinion, finding that unambiguous contract language doomed the revival of a lawsuit from a retired employee who said his monthly benefit was unfairly reduced.

  • December 08, 2025

    Chancery Blocks Opt-Out In $32M Emisphere Settlement

    The Delaware Chancery Court on Monday signed off on a $32 million class settlement over Emisphere Technologies Inc.'s $1.8 billion sale to Novo Nordisk AS, rejecting Emisphere investor IsZo Capital LP's push to opt out and pursue its own claims and trimming the investors' fee request to a 23.5% cut of the fund.

  • December 08, 2025

    4 Firms Lead $1.51B TC Transcontinental Packaging Deal

    Private equity-backed ProAmpac on Monday unveiled plans to acquire TC Transcontinental Packaging from TC Transcontinental in a $1.51 billion deal built by four law firms.

  • December 08, 2025

    Hi-Tech Pharma, CEO Want New Trial In Feds' Fraud Case

    A health supplement company's CEO, who was largely acquitted of federal fraud and conspiracy charges last month, asked a Georgia federal judge Friday to toss the lone conviction he faced, arguing that allowing the charge to stand "would constitute a miscarriage of justice."

  • December 08, 2025

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court delivered a busy first week of December, featuring commercial disputes, post-closing merger and acquisition battles and renewed scrutiny of fiduciary conduct ranging from oil and gas investments to healthcare acquisitions. 

  • December 08, 2025

    High Court Wants Feds' Input On Health Workers' Vax Fight

    The U.S. Supreme Court asked Monday for the federal government's input on a group of religious workers' challenge to a pandemic-era New York state policy requiring healthcare providers to make their employees be vaccinated against COVID-19.

  • December 05, 2025

    Juror Who Alleged Misconduct Dismissed From Opioid Trial

    A juror in Florida hospitals' $1.5 billion trial against the three major pharmacy chains over opioid dispensing was dismissed Friday after a judge found that her allegations of serious misconduct against another juror were largely unwarranted.

  • December 05, 2025

    SG Urges Justices To Hear Hikma's 'Skinny Label' Patent Case

    The U.S. solicitor general on Friday urged the U.S. Supreme Court to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent suit involving its "skinny label" on a generic heart drug, saying the ruling puts the availability of lower-cost generics at risk.

  • December 05, 2025

    Judge Won't Lift Stay On Hopewell Drug Launch

    A Delaware federal judge has shot down Hopewell Pharma Ventures' bid to lift a regulatory stay on approval of its planned generic version of German drugmaker Merck's blockbuster multiple sclerosis drug Mavenclad.

  • December 05, 2025

    ITC Bans Infringing Drill Bit Imports After Fed. Circ. Remand

    The U.S. International Trade Commission has held that a group of foreign companies is violating Section 337 of the Tariff Act by shipping diamond drill bit components that infringe a U.S. company's patent and issued an order banning such imports after the case was remanded by the Federal Circuit.

Expert Analysis

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • Ruling On Labor Peace Law Marks Shift For Cannabis Cos.

    Author Photo

    Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.

  • Fed. Circ. Rulings Refine Patent Claim Construction Standards

    Author Photo

    Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft.

  • How Value-Based Patent Fees May Shape IP Strategies

    Author Photo

    If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary.

  • Agentic AI Puts A New Twist On Attorney Ethics Obligations

    Author Photo

    As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG.

  • Using Reissue Applications To Strategically Improve Patents

    Author Photo

    Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield.

  • FDA Transparency Plans Raise Investor Disclosure Red Flags

    Author Photo

    The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter.

  • Series

    Being A Professional Wrestler Makes Me A Better Lawyer

    Author Photo

    Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability.

  • Patent Claim Lessons From Fed. Circ.'s Teva Decision

    Author Photo

    The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.